title: Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications.
abstract: Microvascular complications are the leading causes of acquired blindness, end-stage renal failure, and varieties of neuropathy associated with diabetes. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is involved in endothelial dysfunction, oxidative stress, and inflammation associated with the progression of diabetic microvascular complications. Elevated ADMA has been detected in experimental animals and patients with diabetic microangiopathy like retinopathy, nephropathy, and neuropathy. In the review, we focus on the role of ADMA in the pathobiology of major microvascular complications of diabetes.
authors.affiliation: *Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China;†Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, Sichuan, China; and‡Provincial Key Laboratory of Cardiovascular Research, Central South University, Changsha, China.
authors.forename: Mei-Rong
authors.initials: MR
authors.lastname: Du
authors.forename: Gui-Xia
authors.initials: GX
authors.lastname: Ju
authors.forename: Nian-Sheng
authors.initials: NS
authors.lastname: Li
authors.forename: Jun-Lin
authors.initials: JL
authors.lastname: Jiang
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000473:pathology; D003925:Diabetic Angiopathies / Q000378:metabolism* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000378:metabolism; D006801:Humans; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D015415:Biomarkers; D004791:Enzyme Inhibitors; C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase